To include your compound in the COVID-19 Resource Center, submit it here.

Mesoblast, Teva deal

Teva returned rights to Mesoblast’s mesenchymal precursor cell (MPC) technology for cardiovascular indications,

Read the full 136 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE